ITEM 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) At a regularly scheduled meeting of the Board of Directors (the "Board") of Synta Pharmaceuticals Corp. (the "Company") held on March 5, 2013, the Board determined to move one of the directors from Class III into Class I to achieve a more equal balance of membership among the classes of directors. Accordingly, at the March 5, 2013 meeting, Donald W. Kufe, M.D. agreed to resign as a Class III director, and he was immediately reappointed to the Board as a Class I director for a term that will expire at the Company's 2014 annual meeting of stockholders. The resignation and reappointment of Dr. Kufe was effected solely to satisfy certain legal requirements under the Delaware General Corporation Law and the Company's charter and bylaws in order to rebalance the Board classes, and for all other purposes, including vesting and other compensation matters, Dr. Kufe's service on the Board is deemed to have continued uninterrupted. Dr. Kufe does not serve on any committees of the Board. The Board now consists of two Class I directors, two Class II directors and two Class III directors.

(d) The information set forth above in Item 5.02(b) is incorporated by reference herein.

---